JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Bret Christensen, the Chief Executive Officer of biote Corp. (NASDAQ:BTMD), has recently purchased 37,595 shares of the company’s Class A Common Stock. The acquisition, which took place on March 17, 2025, was conducted at a weighted average price of $3.87 per share, resulting in a total transaction value of $145,492. According to InvestingPro data, the stock currently trades at $4.07, with analyst price targets ranging from $6 to $9, suggesting potential upside from current levels.
This stock purchase was executed through multiple transactions at prices ranging from $3.55 to $4.00 per share. Following this acquisition, Christensen holds a total of 37,595 shares directly. The purchase underscores Christensen’s confidence in the company’s future prospects as he continues to lead biote Corp., a firm specializing in medicinal chemicals and botanical products. The company, with a market capitalization of $147 million, boasts impressive gross margins of 70.5% and annual revenue of $197 million. InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about BTMD’s financial health and growth prospects.
In other recent news, Biote Corp. reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.10, which was slightly below the forecasted $0.11. The company also reported revenue of $49.8 million, falling short of the expected $51.29 million. Following these results, Jefferies and Truist Securities both adjusted their price targets for Biote, with Jefferies setting a new target of $6.80 and Truist at $7.00, while both firms maintained a Buy rating on the stock. The analysts attributed these adjustments to operational challenges, particularly the implementation of new software, which has affected the company’s growth trajectory.
Despite the earnings miss, Biote’s board and CEO Bret Christensen showed confidence in the company’s future by purchasing approximately 260,000 shares of common stock. This move is seen as a testament to their belief in the company’s long-term strategy. Additionally, the company launched the BioTRx wellness platform and expanded its manufacturing capabilities, signaling strategic initiatives aimed at fostering growth. The company has set its 2025 revenue guidance between $200 million and $280 million, with an anticipated growth in procedure revenue and dietary supplement revenue. Analysts from Jefferies and Truist remain optimistic about Biote’s potential to navigate current challenges and return to a growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.